iTeos to Participate in Upcoming Investor Conferences
Rhea-AI Summary
iTeos Therapeutics (Nasdaq: ITOS), a clinical-stage biopharmaceutical company focused on immuno-oncology therapeutics, has announced its participation in two upcoming investor conferences in September 2024. The company will be present at the Wells Fargo Healthcare Conference on September 4 in Boston, and the Cantor Fitzgerald Global Healthcare Conference on September 18 in New York.
At both events, iTeos management will engage in fireside chats and one-on-one investor meetings. The Wells Fargo conference presentation is scheduled for 4:30 PM ET, while the Cantor Fitzgerald conference presentation will take place at 10:20 AM ET. Interested parties can access live webcasts of the presentations through the Investors section of iTeos' website, with archived replays available for approximately 30 days post-event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ITOS declined 1.69%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 28, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming investor conferences in September:
2024 Wells Fargo Healthcare Conference
Format: Fireside chat and one-on-one investor meetings
Date: Wednesday, September 4, 2024
Time: 4:30 PM ET
Location: Boston, M.A.
Cantor Fitzgerald Global Healthcare Conference
Format: Fireside chat and one-on-one meetings
Date: Wednesday, September 18, 2024
Time: 10:20 AM ET
Location: New York, N.Y.
A live webcast of the conference presentation will be available on the Investors section of the company’s website at www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes three clinical-stage programs targeting novel, validated immunosuppressive pathways designed with optimized pharmacologic properties for improved clinical outcomes, including the TIGIT/CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.
Internet Posting of Information
iTeos routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com. The Company encourages investors and potential investors to consult our website regularly for important information about iTeos.
For further information, please contact:
Investor Contact:
Carl Mauch
iTeos Therapeutics, Inc.
carl.mauch@iteostherapeutics.com
Media Contact:
media@iteostherapeutics.com
FAQ
What investor conferences will iTeos Therapeutics (ITOS) attend in September 2024?
When and where is iTeos Therapeutics (ITOS) presenting at the Wells Fargo Healthcare Conference?
What is the format of iTeos Therapeutics' (ITOS) participation in the September 2024 investor conferences?
How can investors access iTeos Therapeutics' (ITOS) conference presentations in September 2024?
